Study of Shenling-Baizhu granule combined with saccharomyces boulardii treatment for pediatric antibiotic associated diarrhea

Abstract

Objective To observe Shenling-Baizhu granule combined with saccharomyces boulardii treatment for pediatric antibiotic associated diarrhea (AAD). Methods A total of 146 children with AAD were randomly divided into the control group (n=73) and the observation group (n=73). The control group received the saccharomyces boulardii, and the observation group received saccharomyces boulardii and Shenling-Baizhu granule, with a course of 5 days. The CD4 and CD8 T lymphocytes were detected by flow cytometry. The stool frequency, stool frequency recovery time, and clinic effects were compared. Results The stool frequency (3.0 ± 0.4 times/d vs. 3.6 ± 0.4 times/d, t=2.624), stool frequency recovery time (3.2 ± 0.6 d vs. 4.5 ± 0.8 d, t=2.641), and recovery time (4.1 ± 0.8 d vs. 5.3 ± 1.1 d, t=2.522) in observation group were significantly lower than those in control group (P<0.05). After the treatment, the CD4+ (38.65% ± 5.74% vs. 33.72% ± 5.23%, t=2.452), CD4+/CD8+ (1.92 ± 0.38 vs. 1.45 ± 0.26, t=2.483) of the observation group was significantly higher than those of the control group, and the CD8+ (20.15% ± 3.16% vs. 23.21% ± 3.44%, t=2.483) of the observation group was significantly lower than this of the control group (P<0.05). The rate of clinic effects was 93.2% (68/73) in observation group, which was higher than 80.8% (59/73) in control group (χ2=2.446, P<0.05). Conclusions The Shenling-Baizhu granule combined with saccharomyces boulardii could enhance the immune function in children with AAD with significant clinical efficacy. Key words: Diarrhea; Child; Antibiotic associated; Shenling-Baizhu granule; Saccharomyces boulardii